TCGA-73-A9RS-01A-11R-A41B-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 41
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.380
- E2F_TARGETS+0.300
- SPERMATOGENESIS+0.300
- MTORC1_SIGNALING+0.260
- G2M_CHECKPOINT+0.250
- CHOLESTEROL_HOMEOSTASIS+0.220
- MYC_TARGETS_V2+0.140
- MYC_TARGETS_V1+0.130
- DNA_REPAIR+0.080
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- ANGIOGENESIS-0.510
- HEDGEHOG_SIGNALING-0.510
- WNT_BETA_CATENIN_SIGNALING-0.510
- TGF_BETA_SIGNALING-0.500
- APICAL_JUNCTION-0.440
- ALLOGRAFT_REJECTION-0.420
- IL6_JAK_STAT3_SIGNALING-0.420
- INFLAMMATORY_RESPONSE-0.420
- APICAL_SURFACE-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.911 |
| 2 | TCGA-86-7955-01A-11R-2187-07 | — | cohortA4 | 0.894 |
| 3 | MNG87 | — | — | 0.888 |
| 4 | 080d03cb-01ea-4dc7-af41-12e3f3877283 | — | — | 0.886 |
| 5 | C3L-00080 | — | cohortA3 | 0.886 |
| 6 | TCGA-E7-A85H-01A-11R-A352-07 | — | — | 0.880 |
| 7 | SRR12475110 | — | — | 0.875 |
| 8 | SRR26320088 | — | — | 0.874 |
| 9 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.868 |
| 10 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.866 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.030 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.010 | Inavolisib | — uncovered |